Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Operating Expenses (2016 - 2025)

Aptevo Therapeutics' Operating Expenses history spans 11 years, with the latest figure at $7.6 million for Q3 2025.

  • For Q3 2025, Operating Expenses rose 45.98% year-over-year to $7.6 million; the TTM value through Sep 2025 reached $26.7 million, up 8.52%, while the annual FY2024 figure was $24.6 million, 14.81% down from the prior year.
  • Operating Expenses for Q3 2025 was $7.6 million at Aptevo Therapeutics, up from $6.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $9.3 million in Q1 2021 and bottomed at $5.2 million in Q3 2024.
  • The 5-year median for Operating Expenses is $7.6 million (2025), against an average of $7.3 million.
  • The largest annual shift saw Operating Expenses dropped 26.34% in 2024 before it skyrocketed 45.98% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $7.7 million in 2021, then dropped by 0.27% to $7.7 million in 2022, then dropped by 16.93% to $6.4 million in 2023, then fell by 0.02% to $6.4 million in 2024, then rose by 19.24% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Operating Expenses are $7.6 million (Q3 2025), $6.2 million (Q2 2025), and $6.5 million (Q1 2025).